THC Farmaceuticals, Inc. (CBDG)
USD 0.01
(8.0%)
USD 0.01
(8.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | -25 Thousand USD | -270.26% |
| 2022 | 14.68 Thousand USD | -23.08% |
| 2021 | 19.08 Thousand USD | -51.46% |
| 2020 | 39.32 Thousand USD | -76.26% |
| 2019 | 165.65 Thousand USD | 525.1% |
| 2018 | 26.5 Thousand USD | 34.9% |
| 2017 | 19.64 Thousand USD | -87.13% |
| 2016 | 152.58 Thousand USD | 0.0% |
| 2014 | 30.75 USD | 25.9% |
| 2013 | 24.43 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 Q3 | 5373.00 USD | -47.95% |
| 2022 Q1 | 10.73 Thousand USD | 0.0% |
| 2022 Q2 | 10.32 Thousand USD | -3.85% |
| 2021 FY | 19.08 Thousand USD | -51.46% |
| 2020 FY | 39.32 Thousand USD | -76.26% |
| 2020 Q1 | 14.47 Thousand USD | 0.0% |
| 2019 Q3 | 55.35 Thousand USD | 21.63% |
| 2019 FY | 165.65 Thousand USD | 525.1% |
| 2019 Q2 | 45.51 Thousand USD | 0.0% |
| 2018 FY | 26.5 Thousand USD | 34.9% |
| 2017 FY | 19.64 Thousand USD | -87.13% |
| 2016 FY | 152.58 Thousand USD | 0.0% |
| 2015 Q2 | 19.85 USD | 90.07% |
| 2015 Q1 | 10.45 USD | 18.1% |
| 2015 Q3 | 35.39 USD | 78.25% |
| 2014 Q2 | 4.18 USD | -69.16% |
| 2014 Q1 | 13.57 USD | 285.24% |
| 2014 FY | 30.75 USD | 25.9% |
| 2014 Q4 | 8.84 USD | 112.85% |
| 2014 Q3 | 4.16 USD | -0.69% |
| 2013 FY | 24.43 USD | 0.0% |
| 2013 Q2 | 3.70 USD | 0.0% |
| 2013 Q3 | 4.34 USD | 17.29% |
| 2013 Q4 | 3.52 USD | -18.75% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 101.872% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 100.496% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 100.085% |
| Nascent Biotech, Inc. | 2.22 Million USD | 101.121% |
| Rebus Holdings, Inc. | 664 Thousand USD | 103.765% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 100.067% |
| Qrons Inc. | 643.67 Thousand USD | 103.884% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 106.417% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 100.044% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 106.017% |
| Skye Bioscience, Inc. | 13.54 Million USD | 100.185% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 100.029% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.508% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 109.552% |
| SQZ Biotechnologies Company | 85.61 Million USD | 100.029% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 100.857% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 101.665% |
| Mesoblast Limited | 5.9 Million USD | 100.424% |
| Marizyme, Inc. | 19.23 Million USD | 100.13% |
| Genus plc | 147.7 Million USD | 100.017% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 100.285% |
| Pharming Group N.V. | 225.49 Million USD | 100.011% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 101.22% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 101.864% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 100.3% |
| ContraFect Corporation | 56.88 Million USD | 100.044% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 100.567% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 101.691% |
| IMV Inc. | 37.7 Million USD | 100.066% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 100.896% |
| MultiCell Technologies, Inc. | 567.42 USD | 4505.907% |
| ONE Bio Corp. | 6.44 Million USD | 100.388% |
| Accustem Sciences Inc. | 3.74 Million USD | 100.667% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 100.029% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 104.7% |
| Q BioMed Inc. | 3.43 Million USD | 100.727% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 100.101% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 100.951% |
| Biomind Labs Inc. | 994.18 Thousand USD | 102.515% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 100.025% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 101.421% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 100.372% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 101.341% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 100.156% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 101.362% |
| GB Sciences, Inc. | 1.42 Million USD | 101.76% |
| Alpha Cognition Inc. | 9.7 Million USD | 100.258% |
| HST Global, Inc. | 140.9 Thousand USD | 117.742% |
| CSL Limited | 3.44 Billion USD | 100.001% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 102.222% |
| Halberd Corporation | 74.84 Thousand USD | 133.404% |
| Enzolytics Inc. | 2.17 Million USD | 101.147% |
| Agentix Corp. | 1.37 Million USD | 101.822% |
| Resverlogix Corp. | 12.71 Million USD | 100.197% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 100.685% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.53 Billion USD | 100.002% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 102.395% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 101.04% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 101.583% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 100.734% |
| AVAX Technologies, Inc. | 7.31 Million USD | 100.342% |
| Zenith Capital Corp. | 8.94 Million USD | 100.28% |
| Genscript Biotech Corporation | 825.34 Million USD | 100.003% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | 243.505% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 101.018% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 114.576% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 101.301% |
| Kadimastem Ltd | 2.41 Million USD | 101.037% |
| Helix BioMedix, Inc. | 1.97 Million USD | 101.268% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 100.23% |
| BioStem Technologies, Inc. | 22.97 Million USD | 100.109% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 113.775% |
| LadRx Corporation | 3.81 Million USD | 100.656% |
| Cell Source, Inc. | 4.32 Million USD | 100.578% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 102.707% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 102.707% |
| NovAccess Global Inc. | 2.46 Million USD | 101.013% |
| Affymax, Inc. | 39.38 Million USD | 100.063% |
| Itoco Inc. | 919.14 Thousand USD | 102.72% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 100.59% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 102.234% |
| Mobile Lads Corp. | 554.54 Thousand USD | 104.508% |
| CytoDyn Inc. | 18.05 Million USD | 100.138% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 199.329% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 111.36% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 101.761% |
| SYBLEU INC | 160.87 Thousand USD | 115.54% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 101.376% |
| International Stem Cell Corporation | 5.27 Million USD | 100.474% |
| Bioxytran, Inc. | 3.82 Million USD | 100.654% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 147.491% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 222.892% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 100.069% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 101.545% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 103.398% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 100.804% |
| Neutra Corp. | 243.82 Thousand USD | 110.253% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 100.143% |
| PureTech Health plc | 144.59 Million USD | 100.017% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 100.122% |
| IXICO plc | 4.7 Million USD | 100.531% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 100.284% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 100.021% |
| CSL Limited | 3.89 Billion USD | 100.001% |
| Cellectis S.A. | 97.32 Million USD | 100.026% |